例）生活習慣病

放射線科（治療部） - 業績一覧（著書・論文）

著書

2023

  1. 「がん・放射線療法2023（秀潤社）」分担執筆：室伏　景子 ・木藤　哲史・清水口　卓也・伊藤　慶
  2. 「強度変調放射線治療における物理技術ガイドライン 2023（日本放射線腫瘍学会）」分担執筆：木藤　哲史・須田　雄飛
  3. 「やさしくわかる放射線治療学 改訂第二版（Gakken）」分担執筆：伊藤　慶
  4. 「ライフライン21がんの先進医療　特集　大腸がん-診断と治療　2023年7月50号（蕗書房）」分担執筆：室伏　景子
  5. 「トリプルネガティブ乳癌 Q&A（医歯薬出版）」分担執筆：清水口　卓也
  6. 「Stereotactic Body Radiation Therapy 2nd Edition: Principles and Practices（Springer）」分担執筆：伊藤　慶 ・中島　祐二朗

2022

  1. 「大腸癌治療ガイドライン2022（金原出版）」分担執筆：室伏　景子
  2. 「乳癌診療ガイドライン2022（金原出版）」システマティックレビュー委員：清水口　卓也
  3. 「人体のメカニズムから学ぶ放射線治療学（メジカルビュー社）」分担執筆：室伏　景子・木藤　哲史
  4. 「がん支持医療テキストブック（日本がんサポーティブケア学会）」分担執筆：室伏　景子・田中　陽子・金丸　友樹・須田　雄飛
  5. 「がん性疼痛 薬の使い方（克誠堂出版）」分担執筆：清水口　卓也・伊藤　慶
  6. 「乳癌診療 state of the art（医歯薬出版）」分担執筆：清水口　卓也
  7. 「強度変調放射線治療 治療計画のコツ: 時間をかけずに的確に行う（学研プラス）」分担執筆：伊藤　慶・中島　祐二朗

2021

  1. 「脊椎SBRTパーフェクトガイド －600症例の経験から－（メディカルアイ）」執筆：伊藤　慶・中島　祐二朗
  2. 「レディオミクス入門（オーム社）」分担執筆：中島　祐二朗・阿部　幸太

2020

  1. 「遺伝性大腸癌診療ガイドライン2020（金原出版）」分担執筆：室伏　景子
  2. 「高齢者がん医療Q&A　臓器別編（金原出版）」分担執筆：室伏　景子
  3. 「詳説非剛体レジストレーション-放射線治療領域-（中外医学社）」編集：木藤　哲史、分担執筆：中島　祐二朗

2019

  1. 「Brachytherapy: Techniques and Evidences（Springer）」分担執筆：室伏　景子

2018

  1. 「放射線治療における非剛体画像レジストレーション利用のためのガイドライン2018年版（日本放射線腫瘍学会）」分担執筆：木藤　哲史

2017

  1. 「がん・放射線療法2017（秀潤社）」編著：唐澤　克之、分担執筆：室伏　景子、早川　沙羅
  2. 「肝癌診療ガイドライン2017（金原出版）」実務協力者：清水口　卓也

2016

  1. 「外部放射線治療におけるQAシステムガイドライン2016年版（日本放射線腫瘍学会）」分担執筆：木藤　哲史
  2. 「放射線治療物理学（国際文献社）」分担執筆：木藤　哲史

2015

  1. 「患者さんと家族のための放射線治療Q&A 2015（金原出版）」分担執筆：待鳥　裕美子・早川　沙羅

2011

  1. 「強度変調放射線治療における物理・技術的ガイドライン 2011（日本放射線腫瘍学会）」分担執筆：木藤　哲史

2010

  1. 「詳説強度変調放射線治療（中外医学社）」分担執筆：木藤　哲史

英文論文

2022

  1. Machitori Y, Ito K, et al. Local Control of Stereotactic Body Radiotherapy with Dynamic tumor Tracking for Lung Tumors: A Propensity Score-Matched Analysis. Jpn J Clin Oncol. 2022
  2. Ito K, et al. Phase 2 Clinical Trial of Separation Surgery Followed by Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord Compression. Int J Radiat Oncol Biol Phys. 2022;112(1):106-113.
  3. Ito K, et al. Fracture risk following stereotactic body radiotherapy for long bone metastases. Jpn J Clin Oncol. 2022;52(1):47-52.

2021

  1. Kurokawa M, Shimizuguchi T, et al. Notable response of SMARCA4-deficient undifferentiated uterine sarcoma to palliative radiotherapy. Adv Radiat Oncol. 2021
  2. Ito K, et al. Novel approach involving stereotactic body radiotherapy followed by intramedullary nail placement for long bone metastases: a case report. Clin Exp Metastasis. 2021;38(4):425-427.
  3. Ito K, et al. Electron beam intraoperative radiotherapy for metastatic epidural spinal cord compression: A prospective observational study. Clin Exp Metastasis. 2021;38(2):219-225.
  4. Ito K, et al. Phase 2 clinical trial of stereotactic body radiotherapy for painful non-spine bone metastases. Practical radiation oncology 2021;11(2):e139-e145.
  5. Ito K, et al. Efficacy and toxicity of re-irradiation spine stereotactic body radiotherapy with respect to irradiation dose history. Jpn J Clin Oncol. 2021;51(2):264-270.
  6. Ito K, et al. Stereotactic body radiotherapy for patients with sacral chordoma who previously received carbon ion therapy. Int J Radiation Oncol Biol Phys. 2020;110(5):1263-1264.
  7. Hayakawa S, Ito K, et al. Safety of biliary stent placement followed by definitive chemoradiotherapy in patients with pancreatic cancer with bile duct obstruction. J Gastrointest Oncol. 2021
  8. Suda Y, et al. Direct energy spectrum measurement of X-ray from a clinical linac. J Appl Clin Med Phys. 2021

2020

  1. Murofushi K, et al. Outcomes analysis of pre-brachytherapy MRI in patients with locally advanced cervical cancer. Int J Gynecol Cancer 30: 473-479, 2020
  2. Murofushi K, et al. Selection criteria and clinical outcomes of patients with asymmetrical cervical cancer treated with various high-dose-rate brachytherapy techniques. Anticancer Res. 40: 999-1006, 2020
  3. Shimizuguchi T et al. Radiation therapy and the risk of herpes zoster in patients with cancer: Cancer. 126(15):3552-3559, 2020
  4. Shimizuguchi T et al. Stereotactic body radiation therapy for primary liver tumors with adverse factors: Hepatoma Research. 6, 2020
  5. Ito K, et al. Stereotactic body radiotherapy for bone metastases in patients with colorectal cancer. Jpn J Clin Oncol. 2020;50(12):1442-1446.
  6. Ito K, et al. Appropriate endpoints for stereotactic body radiotherapy for bone metastasis: classification into five treatment groups. Rep Pract Oncol Radiother. 2020;25(1):150-153.
  7. Hirota H, Ito K, et al. Safety of Radiotherapy for Hemodialysis Patients with Cancer. Int J Clin Oncol. 2020;25(5):978-983.
  8. Nakajima et al. Evaluation of the effect of user-guided deformable image registration of thoracic images on registration accuracy among users. Med Dosim. 45(3):206-212, 2020
  9. Nakajima et al. Variations Between Dose-Ventilation and Dose-Perfusion Metrics in Radiation Therapy Planning for Lung Cancer. Adv Radiat Oncol. 5(3):459-465, 2020
  10. Konishi T, Ogawa H, et al. Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study. J Radiat Res. 2020;61(6):969-976.

2019

  1. Ito K, et al. Whole-liver radiotherapy for diffuse liver metastases improves liver enzymes and related factors. Acta Oncol. 2019;58(4):512-514.
  2. Ito K, et al. Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy. Jpn J Clin Oncol. 2019;49(3):270-275.
  3. Ito K, et al. Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study. Jpn J Clin Oncol. 2019;49(9):856-861.
  4. Ito K, et al. A prospective multicentre feasibility study of stereotactic body radiotherapy in Japanese patients with spinal metastases. Jpn J Clin Oncol. 2019
  5. Hashimoto S, et al. Energy dependence of a radiophotoluminescent glass dosimeter for HDR 192Ir brachytherapy source. Med Phys. 2019;46(2):964-972.
  6. Furuya T, et al. Feasibility of spine stereotactic body radiotherapy for patients with large tumors in multiple vertebrae undergoing re-irradiation: Dosimetric challenge using 3 different beam delivery techniques. Med Dosim. 2019;44(4):415-420.

2018

  1. Karasawa K, et al. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up. Technol Cancer Res Treat. 2018
  2. Ito K, et al. Stereotactic Body Radiotherapy for Spinal Metastases: Clinical Experience in 134 cases from a Single Japanese Institution. Technol Cancer Res Treat. 2018
  3. Ito K, et al. Patterns of Intraosseous Recurrence after Stereotactic Body Radiotherapy for Coxal Bone Metastasis. Int J Radiation Oncol Biol Phys, 100(1), 159-161, 2018
  4. Ito K, et al. Postoperative re-irradiation using stereotactic body radiotherapy for metastatic epidural spinal cord compression. Journal of Neurosurgery: Spine. 29(3): 332-338, 2018
  5. Ogawa H, et al. Re-irradiation for painful bone metastases using stereotactic body radiotherapy. Acta Oncol. 2018;57(12):1700-1704.
  6. Hashimoto S, et al. Field-size correction factors of a radiophotoluminescent glass dosimeter for small-field and intensity-modulated radiation therapy beams. Med phys 45(1): 382-390，2018.
  7. Furuya T, et al. Assessing functionality and benefits of comprehensive dose volume prescriptions: An international, multi-institutional, treatment planning study in spine stereotactic body radiation therapy. Pract Radiat Oncol. 2019;9(1):9-15.
  8. Abe K, et al. Impact of a commercially available model-based dose calculation algorithm on treatment planning of high-dose-rate brachytherapy in patients with cervical cancer. J Radiat Res. 59(2):198-206, 2018
  9. Kawamoto T, et al. Clinical outcomes and prognostic factors of chemoradiotherapy for postoperative lymph node recurrence of esophageal cancer. Jpn J Clin Oncol. 48(3): 259-264, 2018
  10. Kawamoto T, et al. Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer. Auris Nasus Larynx. 45(5): 1073-1079, 2018
  11. Kawamoto T, et al. Palliative radiotherapy and chemoradiotherapy in stage IVA/B esophageal cancer patients with dysphagia. Int J Clin Oncol. 23(6): 1076-1083, 2018
  12. Kawamoto T, et al. Intensity-modulated radiotherapy for synchronous cancer of the anal canal and cervix. Oncol Lett. 16(4): 4512-4518, 2018
  13. Kawamoto T, et al. Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancer. Esophagus. 15(4): 256-262, 2018
  14. Kawamoto T, et al. Definitive Radiotherapy for Esophageal Squamous Cell Carcinoma after Allogeneic Hematopoietic Stem Cell Transplantation with Conditioning of Total Body Irradiation. Gan To Kagaku Ryoho. 45(9): 1357-1359, 2018
  15. Kawamoto T, et al. Sacral insufficiency fracture after stereotactic body radiation therapy for sacral metastasis. Clin Case Rep. 6(11): 2293-2294, 2018
  16. Kageyama SI, et al. Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. Oncotarget. 2018;9(27):19368-19378

2017

  1. Shimizuguchi T, et al. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Int J Clin Oncol. 2017, 22(2), 373–379
  2. Ito K, et al. First report of stereotactic body radiotherapy for large-volume spinal tumor. International Cancer Conference Journal 6(4), 149–153, 2017

2016

  1. Kawamoto T, et al. Intramedullary Spinal Cord Metastasis from Breast Cancer Mimicking Delayed Radiation Myelopathy: Detection With (18)F-FDG PET/CT. Nucl Med Mol Imaging. 50(2): 169-70, 2016

2015

  1. Furuya T, et al. Evaluating dosimetric differences in spine stereotactic body radiotherapy: An international multi-institutional treatment planning study. Journal of radiosurgery and SBRT. 3(4): 307-314, 2015

和文論文

2021

  1. 伊藤慶．脊椎転移に対する定位放射線治療－病態に応じた新分類の提案．定位的放射線治療 2021;25: 83-89.
  2. 伊藤慶、中島祐二朗．脊椎SBRTパーフェクトガイド ～600症例の経験から～ Rad Fan 2021年5月
  3. 伊藤慶、中島祐二朗．脊椎SBRT：エビデンスと方法論．臨床放射線 2021;66(6):555-566.
  4. 中島祐二朗．骨転移SBRTのQA．医学物理 2021;41(1):22-26.

2020

  1. 伊藤慶．定位放射線治療：がんロコモ回避への新たなアプローチ．Bone Joint Nerve（BJN）10(3) 2020年7月

2019

  1. 待鳥裕美子．局所症状を呈するオンコロジーエマージェンシー　頭蓋内転移．内科124(2):1557-1560,2019
  2. 伊藤慶．脊椎転移に対する定位放射線治療：実践編．Rad Fan 17(14) 58-61 2019年11月

2018

  1. 唐澤克之．女性における放射線診断ならびに放射線治療による被曝の留意点　胆と膵39(6):569-573, 2018
  2. 川本晃史．全身照射を用いた同種造血幹細胞移植後に発症した食道癌に対して根治的放射線治療を施行した1 例．癌と化学療法45(9) 1357-1359,2018

2017

  1. 唐澤克之．転移のある甲状腺癌に対する放射線療法．日本内分泌・甲状腺外科学会雑誌34(4):2017
  2. 伊藤慶．転移性脊髄圧迫に対する除圧術および定位放射線治療（総説）脊椎脊髄ジャーナル30(7): 677-681, 2017
  3. 柴田友紀子．89SrCl2（89Sr）による骨転移治療．耳鼻咽喉科・頭頸部外科 89(11):2017
  4. 古谷智久．脊椎転移に対する体幹部定位放射線治療：高精度治療導入時における当科のプロセス紹介．Rad Fan 15(14) 17-21 2017年11月

2016

  1. 唐澤克之．PSA再発の定義および治療上の問題点．日本臨床 74(3):2016　
  2. 唐澤克之．各種 IMRT テクニックと新しい放射線治療機器．医学のあゆみ257(1):37-41,2016
  3. 伊藤慶．術後治療として, IMRT を用いて拡大照射を試みた子宮頸癌の1 例．東京産科婦人科学会会誌 65(2): 296-300, 2016
  4. 伊藤慶．脊椎転移に対する定位放射線治療．Rad Fan 14(14) 41-44 2016年11月

2015

  1. 唐澤克之．X線高精度放射線治療からみた粒子線治療．臨床放射線 2015
  2. 唐澤克之．新膵癌治療 -アブラキサン・FOLFIRINOXをどう使うか　放射線治療　TomoTherapy（トモセラピー）の有用性は？肝胆膵 2015
  3. 唐澤克之．画像誘導放射線治療．BIO Clinica 2:2015
  4. 影山俊一郎．合併症を伴う頭頸部扁平上皮がんに対するCetuximab併用放射線治療．臨床放射線 60(13): 2015

放射線科（治療部）